Aim: To develop and evaluate a whole-body physiologically based pharmacokinetic (WB-PBPK) model of bisoprolol and to simulate its exposure and disposition in healthy adults and patients with renal function impairment. Methods: Bisoprolol dispositions in 14 tissue compartments were described by perfusion-limited compartments. Based the tissue composi tionequationsanddrug-specificpropertiessuchaslogP,permeability,andplasmaproteinbindingpublishedinliteratures, the absorption and whole-body distribution of bisoprolol was predicted using the 'Advanced Compartmental Absorption Transit' (ACAT) model and the whole-body disposition model, respectively. Renal and hepatic clearances were simulated using empirical scaling methodsfollowedbyincorpora tionintotheWB-PBPKmodel.Modelrefinementswereconductedafteracomparisonofthesimulated concentration-timeprofilesandpharmacokineticparameterswiththeobserveddatainhealthyadultsfollowingintravenousandoral administration. Finally, the WB-PBPK model coupled with a Monte Carlo simulation was employed to predict the mean and variability of bisoprolol pharmacokinetics in virtual healthy subjects and patients. Results: The simulated and observed data after both intravenous and oral dosing showed good agreement for all of the dose levels in the reported normal adult population groups. The predicted pharmacokinetic parameters (AUC, C max , and T max ) were reasonably consistent(<1.3-folderror)withtheobservedvaluesaftersingleoraladministrationofdosesrangingfromof5to20mgusingtherefined WB-PBPKmodel.Thesimulatedplasmaprofilesaftermultipleoraladministrationofbisoprololinhealthyadultsandpatientwithrenal impairmentmatchedwellwiththeobservedprofiles.
Conclusion:The WB-PBPK model successfully predicts the intravenous and oral pharmacokinetics of bisoprolol across multi ple dose levelsindiversenormaladulthumanpopulationsandpatientswithrenalinsufficiency.